Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

2.

Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC

3.

Best foot forward—chemo care should include podiatry, say researchers

4.

Telemedicine services linked to reducing excess mortality

5.

Inner Thoughts of Leonard Bernstein, the "Maestro".


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot